LEXICON PHARMACEUTICALS, INC.
Close on Oct 19, 2026
- Market cap
- $678.36M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $700.00K | $-0.07 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $21.10M | $-0.01 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 5, 2026 | Before market open | $5.50M | $-0.04 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | $14.20M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | Before market open | $28.90M | $0.01 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | During market hours | $1.30M | $-0.07 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 6, 2025 | During market hours | $26.60M | $-0.09 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | During market hours | $1.80M | $-0.18 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 11, 2024 | Before market open | – | – | – |
Press releases
Announcements Lexicon Pharmaceuticals filed with the SEC
LEXICON PHARMACEUTICALS REPORTS SECOND QUARTER 2026
Results of operations · EX-99.1 to Form 8-K
LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2026
Results of operations · EX-99.1 to Form 8-K
Lexicon Pharmaceuticals Announces $100 Million Loan Facility
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER 2025
Results of operations · EX-99.1 to Form 8-K
LEXICON ANNOUNCES PRICING OF APPROXIMATELY $94.6 MILLION PUBLIC
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
LEXICON ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2025
Results of operations · EX-99.1 to Form 8-K
LEXICON PHARMACEUTICALS REPORTS SECOND QUARTER 2025
Results of operations · EX-99.1 to Form 8-K
LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2025
Results of operations · EX-99.1 to Form 8-K
LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2024
Results of operations · EX-99.1 to Form 8-K
LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2024
Results of operations · EX-99.1 to Form 8-K
LEXICON PHARMACEUTICALS REPORTS SECOND QUARTER 2024
Results of operations · EX-99.1 to Form 8-K
LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2024
Results of operations · EX-99.1 to Form 8-K
LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER 2023
Material agreement · Results of operations · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
ANNOUNCES OVERSUBSCRIBED $250 MILLION PRIVATE PLACEMENT OF EQUITY SECURITIES
Material agreement · Results of operations · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2023
Results of operations · EX-99.1 to Form 8-K
LEXICON PHARMACEUTICALS REPORTS SECOND QUARTER 2023
Results of operations · EX-99.1 to Form 8-K
LEXICON ANNOUNCES PRICING OF $125 MILLION PUBLIC OFFERING AND
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
LEXICON ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2023
Results of operations · EX-99.1 to Form 8-K
LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER 2022
Results of operations · EX-99.1 to Form 8-K
LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2022
Results of operations · EX-99.1 to Form 8-K
LEXICON PHARMACEUTICALS REPORTS SECOND QUARTER 2022
Results of operations · EX-99.1 to Form 8-K
ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ANNOUNCES PRICING OF $85.0 MILLION PUBLIC OFFERING AND
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR SOTAGLIFLOZIN TO TREAT HEART FAILURE
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
LEXICON ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 PROOF-OF-CONCEPT STUDY OF LX9211 IN PAINFUL DIABETIC NEUROPATHY
Other events · EX-99.1 to Form 8-K
LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2022
Results of operations · EX-99.1 to Form 8-K
LEXICON ENTERS INTO LOAN FACILITY WITH OXFORD FINANCE
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE
Results of operations · EX-99.1 to Form 8-K
LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2021
Results of operations · EX-99.1 to Form 8-K